**Hemostatic function one year after liver transplantation**

**(HALT)**

**Case Record Form**

##### Patientnumber: HALT-P |\_\_|\_\_|

|  |  |
| --- | --- |
| **Inclusion criteria**  **(check if patient meets the criterium)** |  |
| Cirrhosis |  |
| >18 years of age |  |
| Signed consent form |  |
| Adequate liver function 1 year after OLT |  |

|  |  |  |
| --- | --- | --- |
| **Exclusion criteria** | **No** | **Yes** |
| Congenital coagulation disorder |  |  |
| Active infection (< 2wk) |  |  |
| Active rejection (biopsy proven) |  |  |
| Use of anticoagulant drugs in the past 10 days |  |  |
| Pregnancy |  |  |
| HIV+ |  |  |
| Recent blood product transfusion (<7 days) |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Background information** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Date of birth** | | | | | | | **|\_\_||\_\_|- |\_\_||\_\_|-|\_\_||\_\_||\_\_||\_\_| dd-mm-yy** | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Gender** | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Height** | | | | | | |  | | | | | | | | | | | **Weight** | | | | | | | | | |  | | | | |
|  | | | | | | |  | | | | | | | | | | | | | | | | |  | | | | | | | | |
| **Indication for OLT** | | | | | | |  | | | | | | | | | | | | | | | | |  | | | | | | | | |
| MELD score  (see labvalues below) | | | | | | | , | | | | | | | | | | | | | | | | | | | | | | | | | |
| Child Pugh score | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | | | | |
| Viral Hepatitis | Yes | | Type | | | | A | | | B | | | | | | | | | | C | | | |  | | | | | | | | |
|  | No | |  | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Primary biliary cirrhosis | | | | | | Yes | | No | | | |  | | | | Hemochromatosis | | | | | | | | | | | Yes | | | | No | |
| Alcoholic cirrhosis | | | | | | Yes | | No | | | |  | | | | PSC | | | | | | | | | | | Yes | | | | No | |
| NASH | | | | | Yes | | | No | | |  | | | | | Auto-immune hepatitis | | | | | | | | | | | Yes | | | | No | |
| Wilson’s disease | | | | | Yes | | | No | | |  | | | | | Antitrypsin deficiency | | | | | | | | | | | Yes | | | | No | |
| Other: ­­­­­­­­­­­­­­­­­­­­­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Recurrent disease** | | | | | | | | | | | | | | **Yes** | | | | | | | | | | | | **No** | | | | | | |
| **Date of OLT** | | | | | | | | | | | | | | **|\_\_||\_\_|- |\_\_||\_\_|-|\_\_||\_\_||\_\_||\_\_| dd-mm-yy** | | | | | | | | | | | | | | | | | | |
| **Type of graft** | | | | | | | | | | | | | | **Full-size** | | | | | | | | | | | | **Split** | | | | | | |
|  | | | | | | | | | | | | | | **domino** | | | | | | | | | | | | **FAP** | | | **Yes No** | | | |
| **Complications Tx** | | | | | | | | | | | | | | early (< 2 weken) | | | | | | | | | | | | Late (> 2 weken) | | | | | | |
|  | | | | | | | | | | | | | | **Yes** | | | | | | | **No** | | | | | **Yes** | | | | | | **No** |
| Portal vein thrombosis | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Hepatic artery thrombosis | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Wound infection | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Peritonitis | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Pulmonary embolism | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Deep vein thrombosis | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Pleural effusion | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Pneumonia | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| DM de novo | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Obesity | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Hypertension | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Hypercholesterolemia | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Acute rejection | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Chronic rejection | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Delayed graft function (asat >2000 day 2-7) | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| ITBL | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| Other | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
|  | | | | | | | | | | | | | |  | | | | | | | | | | | |  | | | | | | |
| **Number of relaparotomies** | | | | | | | | | | | | | | **|\_\_|\_\_|** | | | | | | | | | | | | | | | | | | |
| **Immunesupressants:** | | | | | | | | | | | | | | **Yes** | | | | | | | | | | | | **No** | | | | | | |
| Postoperative | | | | Tacrolimus | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Cyclosporine (neoral) | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Prednisone | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Azathioprine | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Cellcept | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Sirolimus | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Simulect (basiliximab) | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
| Current | | | | Tacrolimus | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Cyclosporine | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Prednisone | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Azathioprine | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Cellcept | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Siroliumus | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
|  | | | | Simulect (basiliximab) | | | | | | | | | | |  | | | | | | | |  | | | | | | | | | |
| **Co-morbidities:** | | | | | | | | |  | | | | | | | | | | | | |  | | | | | | | | | | |
| **Cardiovascular** | | | | | | | | | **Yes |\_\_|, which one** | | | | | | | | | | | | | **No |\_\_|** | | | | | | | | | | |
| Hypertension | | | | | | | | |  | | | | | | | | | | | | |  | | | | | | | | | | |
| Angina pectoris | | | | | | | | |  | | | | | | | | | | | | |  | | | | | | | | | | |
| Myocardial infarction | | | | | | | | |  | | | | | | | | | | | | |  | | | | | | | | | | |
| Intermittent claudication | | | | | | | | |  | | | | | | | | | | | | |  | | | | | | | | | | |
| Other: | | | | | | | | |  | | | | | | | | | | | | |  | | | | | | | | | | |
| **Systemic disease** | | | | | | | | **Yes |\_\_|, which one** | | | | | | | | | | | | | | **No |\_\_|** | | | | | | | | | | |
|  | | | | | | | | Yes | | | | | | | | | | | Post OLT? | | | | | | No | | | | | | | |
| Diabetes mellitus | | | | | | | | I | | | | | II | | | | | | Resolved:  Yes  No | | | | | |  | | | | | | | |
| Thyroid disease | | | | | | | |  | | | | | | | | |  | | | | | | | |  | | | | | | | |
| Renal disease: | | | | | | | |  | | | | | | | | |  | | | | | | | |  | | | | | | | |
| Hepatorenalsyndrome pre-OLT | | | | | | | |  | | | | | | | | |  | | | | | | | |  | | | | | | | |
| Hepatorenal syndrome post-OLT | | | | | | | |  | | | | | | | | |  | | | | | | | |  | | | | | | | |
| Diabetic nefropathy | | | | | | | |  | | | | | | | | |  | | | | | | | |  | | | | | | | |
| Other: | | | | | | | |  | | | | | | | | |  | | | | | | | |  | | | | | | | |
|  | | | | | | | |  | | | | | | | | |  | | | | | | | |  | | | | | | | |
| Intestinal disease | | Colitis Ulcerosa | | | | | | |  | | | | | | | |  | | | | | | | |  | | | | | | | |
| M. Crohn | | | | | | |  | | | | | | | |  | | | | | | | |  | | | | | | | |
| Other | | | | | | | **:** | | | | | | | | | | | | | | | | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** | | | | | | | |
| **Oncological illness** | | | | | | | | | **Yes |\_\_|, which one** | | | | | | | | | | | | | | | | **No |\_\_|** | | | | | | | |
|  | | | | | | | | | **Basal cell carcinoma** | | | | | | | | | | | | | | | | Yes | | | | | No | | |
|  | | | | | | | | | **Other malignancy** | | | | | | | | | | | | | | | |  | | | | |  | | |
|  | | | | | | | | | Current (to be treated or currently treated) | | | | | | | | | | | | | | | | Yes | | | | | No | | |
|  | | | | | | | | | Treated | | | | | | | | | | | | | | | | Yes | | | | | No | | |
|  | | | | | | | | | Treated with curative intent >5 years ago | | | | | | | | | | | | | | | | Yes | | | | | No | | |
|  | | | | | | | | | Palliative treatment | | | | | | | | | | | | | | | | Yes | | | | | No | | |
| **Intoxications** | | | | | | | | | **Yes |\_\_|, which ones** | | | | | | | | | | | | | | | | **No |\_\_|** | | | | | | | |
| **Smoking** | | | | | | | | | ……sigarettes daily | | | | | | | | | | | | | | | |  | | | | | | | |
| Alcohol | | | | | | | | | ...Units  daily weekly | | | | | | | | | | | | | | | |  | | | | | | | |
| Other | | | | | | | | | : | | | | | | | | | | | | | | | | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | | |

|  |  |  |
| --- | --- | --- |
| **Medication:** | **No |\_\_|** | **Yes |\_\_|, which ones:** |
|  | |  |
|  | |  |
|  | |  |
|  | |  |
|  | |  |
|  | |  |
|  | |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Laboratory measure** |  |  | | |
| Sample | Date (dd/mm/yy) | |\_\_|\_\_|/|\_\_|\_\_|/|\_\_|\_\_| **Not assessed** | | |
|  | Time (hh:mm) | |\_\_|\_\_|:|\_\_|\_\_| | |  |
|  |  |  |  |  |
| Hematology | Hemoglobin |  | (mmol/L) | |\_\_|\_\_|.|\_\_| |\_\_| |
|  | Leukocytes |  | (x 109/L) | |\_\_|\_\_|.|\_\_| |\_\_| |
|  | Platelets |  | (x 109/L) | |\_\_|\_\_|\_\_| |\_\_| |
|  | Hematocrit |  | (L/L) | |\_\_|\_\_| |\_\_| |
|  |  |  |  |  |
| Hemostasis | PT |  | sec | |\_\_|\_\_|\_\_| |\_\_| |
|  | APTT |  | sec | |\_\_|\_\_|\_\_| |\_\_| |
|  | INR |  |  | |\_\_|.|\_\_| |\_\_| |
|  | Fibrinogen |  | g/L | |\_\_|.|\_\_| |\_\_| |
|  | AT | | % | |\_\_|\_\_| |\_\_| |
| Clinical chemistry | Potassium | | (mmol/l) | |\_\_|.|\_\_| |\_\_| |
| Sodium | | (mmol/l) | |\_\_|\_\_|\_\_| |\_\_| |
| Urea | | (mmol/l) | |\_\_|.|\_\_| |\_\_| |
|  | Serum creatinin | | (μmol/L) | |\_\_|\_\_|\_\_| |\_\_| |
|  | ASAT | | (E/L) | |\_\_|\_\_|\_\_| |\_\_| |
|  | ALAT | | (E/L) | |\_\_|\_\_|\_\_| |\_\_| |
|  | AF | | (E/L) | |\_\_|\_\_|\_\_| |\_\_| |
|  | LDH | | (E/L) | |\_\_|\_\_|\_\_| |\_\_| |
|  | CRP | | (mg/L) | |\_\_|\_\_|\_\_| |\_\_| |
|  | Billirubin direct | | (μmol/L) | |\_\_|\_\_|\_\_| |\_\_| |
|  | Billirubin indirect  Albumin | | (μmol/L)  (g/L) | |\_\_|\_\_|\_\_| |\_\_|  |\_\_|\_\_| |\_\_| |
|  | Y-GT  Gluc  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | (E/L)  (mmol/l) | |\_\_|\_\_|\_\_| |\_\_|  |\_\_|\_\_|.|\_\_| |\_\_|  |\_\_|\_\_|.|\_\_| |\_\_| |

|  |
| --- |
| **Remarks:** |
|  |